Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer

NCT01872260 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01872260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01872260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
October 22, 2013
Completion date
February 26, 2027
Enrollment
259 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer